Epstein Secrets

rill Lynch, Pierce, Fenner & Smith Incorporated The power of global connectionsTM From: Ens, Amanda Sent: Wednesday, August 24, 2016 3:30 PM To: 'Richard Kahn' Subject: RE: TEVA...IPR Decision Coming By Thurs...I like the Risk/Reward (+10% vs -5%) Rich, right after I sent this, the ruling came in earlier a

Jeffrey E." <[email protected]> To: Richard Kahn Subject: Re: Add to TEVA and AGN Date: Thu, 25 A

ew (S58ish) while a negative outcome likely sees 5% downside to around $50/sh (given a Cons already assumes generic competition coming next year). Copaxone Litigation Timeline (from 2O Results Slidedeck) Scenario Analysis — BofAML Daniel Lundquist EFTA00820344 Healthcare Specialist Sales Global Equities Bank of Ameri

rill Lynch, Pierce, Fenner & Smith Incorporated The power of global connections"' From: Ens, Amanda Sent: Wednesday, August 24, 2016 3:30 PM To: 'Richard Kahn' Subject: RE: TEVA...IPR Decision Coming By Thurs...I like the Risk/Reward (+10% vs -5%) Rich, right after I sent this, the ruling came in earlier a

"Jeffrey E." <[email protected]> To: Richard Kahn Subject: Re: Add to TEVA and AGN Date: Thu, 25 A

ew (S58ish) while a negative outcome likely sees 5% downside to around $50/sh (given a Cons already assumes generic competition coming next year). Copaxone Litigation Timeline (from 2Q Results Slidedeck) Scenario Analysis — BofAML EFTA00820353 Daniel Lundquist Healthcare Specialist Sales Global Equities The power of

From: Richard Kahn • To: "Jeffrey E." <[email protected]> Subj

From: Richard Kahn • To: "Jeffrey E." <[email protected]> Subject: Re: Add to TEVA and AGN Date: Thu, 25 Aug 2016 16:43:38 +0000 agreed her frequent recommendati

le a negative outcome likely sees 5% downside to around $50/sh (given a Cons already assumes generic competition coming next year). EFTA00665659 Copaxone Litigation Timeline (from 2Q Results Slidedeck) Scenario Analysis — BofAML Daniel Lundquist Healthcare Specialist Sales Global Equities Bank of America Merrill Lync